Daewoong Pharmaceutical and Inventage Lab, a startup specializing in drug delivery system (DDS) platform, have agreed to develop male baldness therapy, IVL3001 and IVL3002.

IVL3001 and IVL3002 are long-term hair-loss solutions to be developed from Daewoong’s pipeline and will be administered once every month or three months. Inventage Lab’s DDS technology, Involucrin (IVL)-Precision Particle Fabrication Microsphere, is equipped with male hair loss therapy.

Finasteride, the ingredient of IVL3001 and IVL3002, is one of the verified materials approved by the U.S. Food and Drug Administration. It has proven its efficacy and safety in preventing hair loss and has been widely used.

IVL3001, a month-long acting drug for male hair loss, is scheduled to be released in 2024 with a phase 1 clinical trial planned in early 2021. IVL3002, a three month-acting hair loss treatment, is undergoing non-clinical trials.

“Daewoong Pharmaceutical has various pipelines, including anticancer drugs, central nervous system, and obesity, based on 20 years of production and research experience in long-acting injection,” Daewoong Pharmaceutical CEO Jeon Seng-ho said. “We are planning to speed up the development of long-acting male hair loss therapies to enter the global market.”

Inventage Lab Kim Ju-hee said, “It is a very valuable opportunity to combine our innovative platform tech with Daewoong Pharmaceutical, which possesses development expertise and sales network,”